Issue 1, 2018

Novel cell-penetrating-amyloid peptide conjugates preferentially kill cancer cells

Abstract

The goal of this study was to develop a peptide which could use the toxic effects of amyloid, a substance which is the hallmark of over 25 known human diseases, to selectively kill cancer cells. Here we demonstrate that two separate amyloid-forming hexapeptides, one from the microtubule associated protein Tau involved in formation of paired helical filaments of Alzheimer's disease, and the other an amyloid forming sequence from apolipoprotein A1, when conjugated to a cell penetrating peptide (CPP) sequence, form toxic oligomers which are stable for up to 14 h and able to enter cells by a combination of endocytosis and transduction. The amyloid peptide conjugates showed selective cytotoxicity to breast cancer, neuroblastoma and cervical cancer cells in culture compared to normal cells. Fluorescence imaging experiments showed the CPP–amyloid peptide oligomers formed intracellular fibrous amyloid, visible in the endosomes/lysosomes, cytosol and nucleus with thioflavin S (ThS) staining. Further experiments with rhodamine-conjugated Dextran, propidium iodide (PI), and acridine orange (AO) suggested the mechanism of cell death was the permeability of the lysosomal membrane brought about by the formation of amyloid pores. Cytotoxicity could be abrogated by inhibitors of lysosomal hydrolases, consistent with a model where lysosomal hydrolases leak into the cytosol and induce cytotoxicity in subsequent downstream steps. Taken together, our data suggest that CPP–amyloid peptide conjugates show potential as a new class of anti-cancer peptides (ACPs).

Graphical abstract: Novel cell-penetrating-amyloid peptide conjugates preferentially kill cancer cells

Article information

Article type
Research Article
Submitted
26 Jun 2017
Accepted
09 Sep 2017
First published
05 Dec 2017

Med. Chem. Commun., 2018,9, 121-130

Novel cell-penetrating-amyloid peptide conjugates preferentially kill cancer cells

J. R. Veloria, L. Chen, L. Li, G. A. M. Breen, J. Lee and W. J. Goux, Med. Chem. Commun., 2018, 9, 121 DOI: 10.1039/C7MD00321H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements